Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
07:05am, Tuesday, 20'th Feb 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07:00am, Wednesday, 07'th Feb 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
07:00am, Thursday, 14'th Dec 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p
Bicycle Therapeutics to Host R&D Day on December 14
07:00am, Thursday, 30'th Nov 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
07:00am, Thursday, 02'nd Nov 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 30'th Oct 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
04:00am, Thursday, 19'th Oct 2023
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
09:05am, Tuesday, 12'th Sep 2023
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
08:20am, Tuesday, 12'th Sep 2023
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi
Why Shares of Bicycle Therapeutics Were Rising on Monday
02:19pm, Monday, 11'th Sep 2023
Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
07:00am, Monday, 11'th Sep 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
07:00am, Tuesday, 05'th Sep 2023
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p
Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due
07:07pm, Monday, 31'st Jul 2023
Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some resu
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
08:08am, Friday, 14'th Jul 2023
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi
